Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Maternity
  4. Back
  5. Common obstetric problems, maternity assessment
  6. Antepartum haemorrhage (APH) (1036)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Antepartum haemorrhage (APH) (1036)

Warning
Please report any inaccuracies or issues with this guideline using our online form

Definition: bleeding from or in to the genital tract, occurring from 24+0 weeks of pregnancy and prior to birth of the baby.

APH complicated 3-5% of pregnancies – leading cause of perinatal and maternal mortality worldwide.

Risk Factors for APH include:

APH and placental abruption in a previous pregnancy

Threatened miscarriage earlier in their pregnancy

Placenta praevia

Pre-eclampsia

FGR

Polyhydramnios

PPROM

Smoking

Multiple pregnancy

Drug misuse

Advanced maternal age

ART

Causes for APH include:

Unexplained

Placenta praevia

Placental abruption

Uterine rupture

Vasa praevia

Trauma

Cervical lesions

Infection

Malignancy

It is recognised that the volume of blood lost is often underestimated as blood loss may be concealed. It is important to assess for signs of clinical shock as well as fetal compromise or fetal demise as important indicators of volume depletion.

Prompt assessment of maternal and/or fetal compromise is key to establishing if urgent intervention is necessary and will guide your management.

APH Definitions:

Spotting – staining, streaking or blood spotting noted on underwear or sanitary protection.

Minor Haemorrhage – blood loss <50ml that has settled

Major Haemorrhage – blood loss of 50-1000ml, with no signs of clinical shock

Massive Haemorrhage – blood loss >1000ml and/or signs of clinical shock

Recurrent APH – episodes of APH on more than one occasion

Spotting/Minor APH

  • record an accurate, detailed history
    • include onset, amount of bleeding, associated pain, recent intercourse, smear history, associated shortness of breath or dizziness, presence of fetal movements
    • risk factors for placental abruption/praevia should also be sought
  • Record MEOWS – blood pressure, heart rate, respiratory rate, temperature
  • Record urinalysis
  • Gentle abdominal palpation and assessment of fundal height as well as uterine activity
  • Auscultate fetal heart and commence CTG (if over 26 weeks) – if unable to locate FHR with Doppler then USS should be utilised
  • Maternal Rhesus status should be noted
  • Review previous USS reports for documentation of placental site

Speculum Examination/Digital Vaginal Examination

  • Vaginal examination should not be performed until placental site is established
  • In cases of placenta praevia digital vaginal examination should be avoided Placenta Praevia guideline
  • Can be useful to identify cervical dilatation or cause for APH in lower genital tract
  • If clinically suspicious cervix refer to management of cervical abnormalities in pregnancy guideline
  • HVS should be performed if appropriate

Maternal Investigations

  • Should be performed to assess the extent and physiological consequences of APH and will depend on amount of bleeding
  • In minor APH a FBC and G&S should be performed. A coagulation screen is not indicated unless platelet count is abnormal.  BOS Guideline
  • Kleihauer test should be performed in Rhesus D – negative mothers to quantify fetomaternal haemorrhage in order to gauge the dose of anti-D immunoglobulin required. Anti-d

Management

  • Management will depend on severity of bleeding/cause/maternal and fetal compromise
  • Involve senior obstetric consultant/clinician early if concerns
  • Consider IV access (16G) if clinically appropriate
  • Consider antenatal corticosteroid therapy for fetal lung maturation – refer to relevant guidelines
  • All women with APH heavier than spotting and women with ongoing bleeding should remain in hospital at least until bleeding has settled
  • Women presenting with spotting who are no longer bleeding and where placenta praevia has been excluded can go home if initial clinical assessment is reassuring with appropriate consideration to patient’s geographically location.
  • In women with APH >37 weeks gestation consider expediting delivery
  • Following a single episode of APH or recurrent episodes thought to be from a cervical ectropion, subsequent antenatal care need not be altered.
  • Following APH from placental abruption or unexplained causes, the pregnancy should be reclassified in Badgernet as High Risk and antenatal care should be consultant-led with serial growth scans, at least until subsequent growth scans demonstrate normal fetal growth and there is no further risk of APH.

Recurrent APH (more than 1 episode)

  • If recurrent APH, including from unexplained causes, then the pregnancy should be classified in Badgernet as High Risk and antenatal care should be consultant-led with serial growth scans.

Major/Massive Antepartum Haemorrhage

Aims of management:

  • RESUSCITATION
  • DELIVERY and management of Third Stage
  • CORRECT COAGULOPATHY

 

Resuscitation:

  • Resuscitation of the mother is paramount and should be prioritised prior to establishing fetal condition
  • GET HELP – obstetric/anaesthetic/neonatal/haematology
  • Major Obstetric Haemorrhage #2222
  • ABC approach
    • Left lateral tilt
    • Airway = secure airway
    • Breathing
      • apply oxygen - non-rebreathing mask, 15L/min
      • commence pulse oximetry
    • Circulation
      • gain IV access x 2 (16G);
      • Obtain bloods including FBC/Coagulation Screen (including fibrinogen)/Kliehauer/Urea & Electrolytes – send as URGENT and alert laboratory. Consider venous blood gas.
      • Crossmatch as per blood ordering schedule – consider group specific or O negative blood if unable to wait for fully crossmatched blood
      • Commence IV fluids – crystalloid up to 2L; colloid up to 1.5L
      • Continuous pulse and blood pressure recording
      • Consider catheter insertion and monitor urine output hourly
      • Record observations on MOEWS chart
      • Keep the patient warm
    • Assess fetus – CTG/USS

Decide on Delivery

  • Delivery may be needed to control haemorrhage
  • Women with APH and associated maternal and/or fetal compromise are required to be delivered immediately
  • In the presence of maternal and/or fetal compromise delivery should be by Caesarean section with obstetric consultant present (consideration of anaesthetic consultant presence if maternal compromise)
  • Anticipate postpartum haemorrhage – pph link
  • Administer Magnesium Sulphate if gestation <30+0 for fetal neuroprotection. This should not delay delivery if there is evidence of maternal compromise.

Correct Coagulopathy:

  • Disseminated intravascular coagulation (DIC) should be considered
  • Coagulation screen and fibrinogen should be assessed – use near patient testing if available and send samples as URGENT or– alert laboratory.
  • Early liaison with Haematology is paramount
  • Consideration of Fresh Frozen Plasma/Cryoprecipitate

Editorial Information

Last reviewed: 31/12/2021

Next review date: 31/07/2025

Author(s): Julie Murphy.

Version: 1

Approved By: Obstetrics Clinical Guideline Group

Document Id: 1036

References

Antepartum Haemorrhage Green Top Guideline No. 63 RCOG 2011

Practical Obstetric Multi-Professional Training (PROMPT)